

Mangalam Drugs and Organics Limited



Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.
☎ 91-22-22616200 / 6300 / 8787 ☎ 91-22-22619090 • CIN : L24230MH1972PLC116413

REF: MDOL/CS-SE/2024- 25/008

May 23, 2024

To,

Listing Department
BSE Ltd
1st Floor, New Trade Wing,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001.
Scrip Code: 532637

Listing Department
National Stock Exchange of India Limited
“Exchange Plaza”, 5th Floor,
Plot No. C-1, Block G,
Bandra - Kurla Complex,
Bandra(E), Mumbai – 400 051
Symbol: MANGALAM

Sub: Submitting the Machine Readable Form / Legible copy of the Financial Results, already submitted to the exchange dated May 21 2024, pursuant to the advisory given by the Exchange.

Ref: Outcome of the Board meeting for the Financial results submitted to the Exchanges dated May 21 2024

Dear Sir / Madam,

With respect to the captioned subject and mentioned reference Please find attached the Machine Readable Form / Legible copy of the Financial Results, already submitted to the exchanges dated May 21 2024, pursuant to the advisory given by the Exchange.

We request you to take the same on your records.

Thanking You,

Yours faithfully,
For Mangalam Drugs & Organics Limited

GOVARDHAN Digitally signed by: GOVARDHAN
MURLIDHAR DHOOT
DN: CN = GOVARDHAN
MURLIDHAR DHOOT C = IN O =
DHOOT
MURLIDHAR
DHOOT

Govardhan M. Dhoot
Chairman & Managing Director
DIN: 01240086

Mangalam Drugs and Organics Limited



Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.
☎ 91-22-62616200 / 6300 / 8787 ☎ 91-22-62619090 • CIN : L24230MH1972PLC116413

REF: MDOL/CS-SE/2024- 25/006

May 21, 2024

To,
Listing Department
BSE Ltd
1st Floor, New Trade Wing,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001.
Scrip Code: 532637

Listing Department
**National Stock Exchange of India
Limited**
“Exchange Plaza”, 5th Floor,
Plot No. C-1, Block G,
Bandra - Kurla Complex,
Bandra(E), Mumbai – 400 051
Symbol: MANGALAM

Sub: Outcome of the Board Meeting held on Tuesday, May 21, 2024

Ref: Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR Regulations) read with SEBI Circular CIR / CFD / CMD /4 /2015 dated September 09, 2015

Dear Sir / Madam,

With respect to the captioned subject and mentioned reference, we are pleased to inform that the Board of Directors of the Company, in their meeting held today i.e., Tuesday, May 21, 2024 has *inter-alia* transacted, considered and approved the following business:

- The Audited Financial Results (Standalone and Consolidated) along with the Audit Report of the Company in respect of the both for the quarter and Financial Year ended March 31, 2024 pursuant to Regulation 33 of the SEBI LODR Regulations. (A copy of the said results, notes thereto and Auditor's Report is annexed hereto and marked as Annexure I.)
- Appointment of Internal Auditor of the Company for the Financial Year 2024-25. (Brief profile is attached herewith as Annexure II)
- Appointment Secretarial Auditor of the Company for Financial Year 2023-24. (Brief Profile is attached herewith as Annexure – III)
- Large Corporate Disclosure (Annexure – IV)

Pursuant to Regulation 33(3)(d) of the Listing Regulations, we hereby declare that in respect of the Audited Financial Results (Standalone and Consolidated) for the quarter and Financial Year ended March 31, 2024, the statutory Auditors have not expressed any modified opinion(s) in their Audit Reports.

Mangalam Drugs and Organics Limited



Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.

☎ 91-22-62616200 / 6300 / 8787 🌐 91-22-62619090 • CIN : L24230MH1972PLC116413

The Board meeting commenced at 4:30 P.M. and concluded at 7:30 P.M.

We request you to take the same on your records.

Thanking You,

Yours faithfully,

For **Mangalam Drugs & Organics Limited**

GOVARDHAN MURLIDHAR DHOOT
DIR: CN = GOVARDHAN
MURLIDHAR DHOOT C = IN O =
Personal
Date: 2024.05.21 19:32:38 +
09'30'

Govardhan M. Dhoot
Chairman & Managing Director
DIN: 01240086

MANGALAM DRUGS AND ORGANICS LIMITED
CIN - L24230MH1972PLC116413

Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400001.



Statement of Standalone Audited Financial Results for the Quarter and Year Ended March 31, 2024

| Sr.No | Particulars | Quarter Ended | | | (Rs. In Lakhs) | |
|-------|--|------------------|-----------------|-----------------|-------------------|------------------|
| | | 31.03.2024 | | 31.03.2023 | Year Ended | |
| | | Audited | Unaudited | Audited | Audited | Audited |
| 1 | Income from Operations | | | | | |
| | (a) Net Sales and Services from Operations | 10,193.77 | 9,704.60 | 9,027.20 | 36,735.35 | 37,019.54 |
| | (b) Other Operating Income | 29.75 | 29.00 | 83.53 | 124.12 | 205.75 |
| | Total Income from Operations (net) (a+b) | 10,223.52 | 9,733.60 | 9,110.73 | 36,859.47 | 37,225.29 |
| 2 | Expenses | | | | | |
| | (a) Cost of Materials Consumed | 5,155.00 | 4,664.80 | 5,503.00 | 22,475.54 | 27,724.47 |
| | (b) Purchase of Stock in trade | 802.02 | 198.90 | 92.79 | 1065.35 | 1535.52 |
| | (c) Changes in Inventories of, Finished Goods, and Work In Progress and Stock-in-trade | (91.28) | 2,062.81 | 1,496.95 | 910.33 | (4,216.11) |
| | (d) Employee Benefits Expenses | 1,110.65 | 897.12 | 628.52 | 3,907.13 | 3,461.23 |
| | (e) Depreciation and amortization expenses | 385.97 | 362.39 | 274.96 | 1,463.22 | 1,098.89 |
| | (f) Other Expenses | 2,077.10 | 1,212.43 | 1,365.22 | 6,761.75 | 6,147.86 |
| | Total Expenses (a to f) | 9,439.45 | 9,398.44 | 9,361.42 | 36,583.32 | 35,751.86 |
| 3 | Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2) | 784.07 | 335.16 | (250.69) | 276.15 | 1,473.43 |
| 4 | Other Income | 4.76 | 0.19 | 29.22 | 9.80 | 43.56 |
| 5 | Profit / (Loss) from ordinary activities before finance costs and exceptional items (3+4) | 788.83 | 335.35 | (221.47) | 285.95 | 1,516.99 |
| 6 | Finance costs (net) | 395.07 | 330.95 | 343.40 | 1,391.69 | 1,295.61 |
| 7 | Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5-6) | 393.76 | 4.40 | (564.87) | (1,105.74) | 221.38 |
| 8 | Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 9 | Profit/(Loss) from ordinary activities before tax (7-8) | 393.76 | 4.40 | (564.87) | (1,105.74) | 221.38 |
| 10 | Tax Expenses | | | | | |
| | (a) Current Tax | 19.15 | (10.61) | (228.32) | 19.15 | (2.62) |
| | (b) Deferred Tax | 20.00 | (35.00) | 102.00 | (220.00) | 97.00 |
| | Total Tax Expenses (a+b+c+d) | 39.15 | (45.61) | (126.32) | (200.85) | 94.38 |
| 11 | Net Profit(+)/Loss(-) from ordinary activities after tax (9-10) | 354.61 | 50.01 | (438.55) | (904.89) | 127.00 |
| 12 | Extraordinary Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 13 | Net Profit(+)/Loss (-) for the period(11-12) | 354.61 | 50.01 | (438.55) | (904.89) | 127.00 |
| 14 | Share of Profit / (Loss) of associates | | | | | |
| 15 | Minority Interest | | | | | |
| 16 | Net Profit / (Loss) after taxes, minority interest and share of profit / -(loss) of associates (13-14-15) | 354.61 | 50.01 | (438.55) | (904.89) | 127.00 |
| 17 | Other Comprehensive income not reclassified into Profit and loss account (Net of Taxes) | (65.33) | 3.12 | 21.32 | (55.97) | 12.48 |
| 18 | Total Comprehensive Income (16+17) | 289.28 | 53.13 | (417.23) | (960.86) | 139.48 |
| 18 | Paid-up Equity Share Capital (Face value of Rs 10/- per share) | 1,582.82 | 1,582.82 | 1,582.82 | 1,582.82 | 1,582.82 |
| 19 | Reserve excluding Revaluation Reverses as per balance sheet of previous accounting year | | | | 12,651.43 | 13,612.80 |
| 20 | Earnings Per Share (EPS) (of Rs 10/-each not annualised): | | | | | |
| | (a) Basic | 2.24 | 0.32 | (2.77) | (5.72) | 0.80 |
| | (b) Diluted | 2.24 | 0.32 | (2.77) | (5.72) | 0.80 |



[Handwritten Signature]

MANGALAM DRUGS AND ORGANICS LIMITED

CIN - L24230MH1972PLC116413

Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400001.



| Standalone Statement of Assets and Liabilities | | Rs. in Lakhs | |
|--|-----------------------------|-----------------------------|--|
| | As at 31.03.2024 Audited | As at 31.03.2023 Audited | |
| ASSETS | | | |
| A. Non-current Assets | | | |
| (a) Property, Plant and Equipment | 10383.00 | 10763.19 | |
| (b) Right to use assets | 2269.40 | 1951.66 | |
| (c) Capital Work-In-Progress | 0.00 | 0.00 | |
| (d) Other Intangible Assets | 2078.17 | 1521.42 | |
| (e) Intangible Assets Under Development | 773.65 | 948.89 | |
| (f) Financial Assets | | | |
| (i) Investments | 3.45 | 0.43 | |
| (ii) Other Financial Assets | 9.00 | 30.84 | |
| (g) Other Non-current Assets (Capital Advances) | 219.78 | 255.54 | |
| Total Non-current Assets (A) | 15736.45 | 15,471.97 | |
| B. Current Assets | | | |
| (a) Inventories | 12363.97 | 13746.65 | |
| (b) Financial Assets | | | |
| (i) Trade Receivables | 2794.42 | 4653.29 | |
| (ii) Cash and Cash Equivalents | 99.90 | 103.61 | |
| (iii) Bank Balance other than Cash and Cash Equivalents | 0.76 | 0.76 | |
| (iv) Loans | 116.54 | 4.55 | |
| (v) Other Financial Assets | 2868.79 | 729.91 | |
| (c) Other Current Assets (Non Financials) | 1733.62 | 1087.68 | |
| Total Current Assets (B) | 19978.00 | 20,326.45 | |
| TOTAL ASSETS (A + B) | 35714.45 | 35,798.42 | |
| EQUITY AND LIABILITIES | | | |
| A. Equity | | | |
| (a) Equity Share Capital | 1582.82 | 1582.82 | |
| (b) Other Equity | 12651.95 | 13612.80 | |
| Total Equity (A) | 14234.77 | 15,195.62 | |
| B. Non-Current Liability | | | |
| (a) Financial Liabilities | | | |
| i) Borrowings | 1335.41 | 1876.64 | |
| ii) Lease Liabilities | 513.38 | 673.90 | |
| iii) Other Financial Liabilities | 0.05 | 0.05 | |
| (b) Deferred Tax Liabilities (Net) | 1208.59 | 1451.59 | |
| (c) Other Non-Current Liabilities | 327.15 | 229.34 | |
| Total Non-current Liabilities (B) | 3384.58 | 4,231.52 | |
| C. Current Liabilities | | | |
| (a) Financial Liabilities | | | |
| (i) Borrowings | 7459.58 | 4956.71 | |
| (ii) Lease Liability | 540.88 | 721.49 | |
| (iii) Trade Payables | | | |
| Total Outstanding dues to Micro and small enterprises | 825.88 | 1109.99 | |
| Total Outstanding dues of creditors other than micro and small enterprises | 7479.61 | 8432.81 | |
| (iv) Other Financial Liabilities | 849.88 | 625.92 | |
| (b) Other Current Liabilities | 840.31 | 352.34 | |
| (c) Provisions | 98.96 | 134.44 | |
| (d) current tax liabilities | 0.00 | 37.58 | |
| Total Current Liabilities (C) | 18095.10 | 16,371.28 | |
| TOTAL EQUITY AND LIABILITIES (A + B + C) | 35714.45 | 35,798.42 | |



MANGALAM DRUGS AND ORGANICS LIMITED

CIN - L24230MH1972PLC116413

Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400001.



Standalone Cash Flow Statement For the year ended March 31, 2024

(Rs. In Lakhs)

| Particulars | For the Period ended March 31, 2024 Audited | For the Period ended March 31, 2023 Audited |
|--|---|---|
| A. Cash flow from operating activities | | |
| Net profit before tax and extra ordinary items. | (1,105.74) | 221.38 |
| Add / (Less) : | | |
| Depreciation & amortisation | 1,463.22 | 1,098.89 |
| Interest expenses (net) | 1,391.69 | 1,295.61 |
| Dividend Income | (0.04) | (0.05) |
| (Gain)/loss on sale of fixed assets | 5.22 | 0.33 |
| Remeasurements of the defined benefit plans | (78.97) | 17.60 |
| Operating profit before working capital changes | 1,675.38 | 2,633.76 |
| Adjustment for : | | |
| (Increase)/decrease in short term loans and advances | (111.99) | (0.95) |
| (Increase)/decrease in other current assets | (2,784.81) | (40.52) |
| (Increase)/decrease in trade receivables | 1,858.87 | (4.28) |
| (Increase)/decrease in inventory | 1,382.67 | (2,036.09) |
| (Increase)/decrease in other non-current assets | 57.60 | 152.97 |
| Increase/(decrease) in trade payables | (1,237.31) | 4,088.10 |
| Increase/(decrease) in other current liabilities | 487.97 | (190.40) |
| Increase/(decrease) in provisions | 150.90 | (1,118.65) |
| Increase/(decrease) in current lease liabilities | (180.61) | 333.82 |
| Increase/(decrease) in non-current liabilities | 97.81 | (164.54) |
| Increase/(decrease) in non current lease liabilities | (160.52) | 152.50 |
| Increase/(decrease) in deposits | 0.00 | |
| | (439.41) | 1,171.95 |
| Cash generated from operations | 1,235.96 | 3,805.72 |
| Add / (Less) : | | |
| Income Tax (Paid)/ Refund | (19.15) | 2.62 |
| Net cash from operating activities | 1,216.81 | 3,808.33 |
| B. Cash flow from investing activities : | | |
| Purchase of fixed assets including Capital WIP | (1,791.62) | (2,791.37) |
| Sale of fixed assets | 4.10 | 574.09 |
| Sale/(Purchase) of investments | (3.02) | - |
| Divided Income | 0.04 | 0.05 |
| Net cash from investing activities | (1,790.50) | (2,217.23) |
| C. Cash flow from financing activities : | | |
| Proceeds/(repayment) of short term borrowing | 2,502.87 | 247.09 |
| Proceeds/(repayment) of long term borrowing | (541.22) | (633.67) |
| Interest Paid (net) | (1,391.69) | (1,295.61) |
| Net cash used in financing activities | 569.96 | (1,682.19) |
| Net increase / (decrease) in cash and cash equivalents | (3.73) | (91.08) |
| Cash and cash equivalents - opening balance | 103.61 | 194.69 |
| Cash and cash equivalents - closing balance | 99.90 | 103.61 |
| Details of cash and cash equivalent at the end of the Period / Year | | |
| - Cash in hand | 6.71 | 4.28 |
| - Balance in current and deposit accounts | 93.20 | 99.33 |
| Total | 99.90 | 103.61 |




MANGALAM DRUGS AND ORGANICS LIMITED

CIN - L24230MH1972PLC116413

Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400001.

**Notes :**

- 1 The above financial results have been prepared in accordance with Indian Accounting Standard (Ind AS) notified under section 133 of the companies Act, 2013, read together with Companies (Indian Accounting Standard) Rules, 2015 and relevant amendment rules thereafter.
- 2 The above audited standalone financial results of the Company for the Quarter and year ended have been reviewed by the Audit Committee and thereafter, approved and taken on record by the Board of Directors of the Company (Mangalam Drugs and Organics Limited) at their meeting held on May 21, 2024.
- 3 The Company's business activity falls within a single reportable Business Segment Viz. "Manufacturing of Bulk Drugs".
- 4 The figures for the quarter ended 31st March, 2024 are the balancing figures between the Audited figures in respect of full financial year upto 31st March 2024 and the unaudited published year-to-date figures upto 31st December 2023 being the date of the end of the third quarter of the financial year respectively whichever subjected to limited review.
- 5 The Board of Directors of the Company at its meeting held on March 15, 2024 had considered and approved the scheme of Merger by Absorption of Mangalam Laboratories Private Limited ("First Transferor Company") and Shri JB Pharma Private Limited (Formerly known as Shri JB Pharma LLP) ("Second Transferor Company") with Mangalam Drugs and Organics Limited ("Transferee Company") and their respective shareholders under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013. The Scheme is subject to the necessary statutory and regulatory approvals including the approvals of Hon'ble National Company Law Tribunal, the shareholders and creditors of each of the companies. As on date, the Scheme is pending for disposal at both Stock Exchanges who shall issue No Objection Certificate under Regulation 37 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- 6 The figures for the previous periods have been regrouped wherever necessary to confirm to the current periods under presentation.

Place: Mumbai
Date: 21st May, 2024On behalf of Board of Directors
For Mangalam Drugs and Organics Limited
Shri Govardhan M. Dhoot
Chairman and Managing Director
DIN:01240086



Independent Auditor's Report on Quarterly and Year to Date Standalone Audited Financial Results of Mangalam Drugs and Organics Limited pursuant to the Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015

The Board of Directors,
Mangalam Drugs and Organics Limited,
Rupam Building, 3rd Floor,
239, P. D'Mello Road, Mumbai 400 001.

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying statement of quarterly and year to date financial results of Mangalam Drugs and Organics Limited (the 'Company') for the quarter ended on March 31, 2023 (the 'statement') and year to date results for the period April 01, 2023 to March 31, 2024 attached herewith, prepared and submitted by the management of the Company pursuant to the requirement of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the Listing Regulations).

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid statement:

- i. is presented in accordance with requirements of the Listing Regulation in this regard; and
- ii. gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Company for the quarter ended March 31, 2024 and the net loss and other comprehensive income and other financial information of the Company for the year ended on March 31, 2024

Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Statements" section of our report. We are independent of the



Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's and Board of Directors responsibilities for the Standalone Annual Financial Statement

The Standalone Annual Financial Statement has been prepared on the basis of the annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit/loss and other comprehensive income of the Company and other financial information in accordance with the applicable accounting standards prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India, and in compliance with Regulation 33 and Regulation 52 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.



- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.


We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The Statement includes the results for the quarter ended March 31, 2024 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2024 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

For V. S. SOMANI & CO.,
Chartered Accountants
Firm Registration No.: 117589



CA. VIDYADHAR SOMANI
Proprietor
Membership No: 102664
UDIN No. 24102664BKEIZT8577

Place: Mumbai
Date: May 21, 2024

MANGALAM DRUGS AND ORGANICS LIMITED

CIN - L24230MH1972PLC116413

Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400001.



| Consolidated Statement of Assets and Liabilities | | Rs. in Lakhs | |
|---|-----------------------------|-----------------------------|--|
| | As at 31.03.2024 Audited | As at 31.03.2023 Audited | |
| ASSETS | | | |
| A. Non-current Assets | | | |
| (a) Property, Plant and Equipment | 10,419.26 | - | |
| (b) Right to use assets | 2,269.41 | - | |
| (c) Capital Work-In-Progress | - | - | |
| (d) Other Intangible Assets | 2,078.17 | - | |
| (e) Intangible Assets Under Development | 773.65 | - | |
| (f) Financial Assets | | | |
| (i) Investments | 0.44 | - | |
| (ii) Other Financial Assets | 9.28 | - | |
| (g) Other Non-current Assets (Capital Advances) | 219.78 | - | |
| Total Non-current Assets (A) | 15,769.99 | - | |
| B. Current Assets | | | |
| (a) Inventories | 12,363.98 | - | |
| (b) Financial Assets | | | |
| (i) Trade Receivables | 2,794.42 | - | |
| (ii) Cash and Cash Equivalents | 90.38 | - | |
| (iii) Bank Balance other than Cash and Cash Equivalents | 0.76 | - | |
| (iv) Loans | 116.54 | - | |
| (v) Other Financial Assets | 472.55 | - | |
| (c) Other Current Assets (Non Financials) | 1,733.80 | - | |
| Total Current Assets (B) | 17,572.43 | - | |
| TOTAL ASSETS (A + B) | 33,342.42 | - | |
| EQUITY AND LIABILITIES | | | |
| A. Equity | | | |
| (a) Equity Share Capital | 1,582.82 | - | |
| (b) Other Equity | 11,996.48 | - | |
| Total Equity (A) | 13,579.30 | - | |
| B. Non-Current Liability | | | |
| (a) Financial Liabilities | | | |
| i) Borrowings | 1,335.41 | - | |
| ii) Lease Liabilities | 513.38 | - | |
| ii) Other Financial Liabilities | 0.05 | - | |
| (b) Deferred Tax Liabilities (Net) | 1,208.59 | - | |
| (c) Other Non-Current Liabilities | 327.15 | - | |
| Total Non-current Liabilities (B) | 3,384.58 | - | |
| C. Current Liabilities | | | |
| (a) Financial Liabilities | | | |
| (i) Borrowings | 7,459.58 | - | |
| (ii) Lease Liability | 540.88 | - | |
| (iii) Trade Payables | | | |
| Total Outstanding dues to Micro and small enterprises | 825.88 | - | |
| Total Outstanding dues of creditors other than micro and small | 5,762.74 | - | |
| (iv) Other Financial Liabilities (other than those specified in item (b)) | 849.88 | - | |
| (b) Other Current Liabilities | 840.61 | - | |
| (c) Provisions | 98.96 | - | |
| (d) current tax liabilities | - | - | |
| Total Current Liabilities (C) | 16,378.53 | - | |
| TOTAL EQUITY AND LIABILITIES (A + B + C) | 33,342.42 | - | |



MANGALAM DRUGS AND ORGANICS LIMITED

CIN - L24230MH1972PLC116413

Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400001.

| Sr.No | Particulars | Quarter Ended | | | Year Ended | |
|--|---|------------------|-----------------|-------------------------|-------------------|----------------------------|
| | | 31.03.2024 | 31.12.2023 | 31.03.2023 | 31.03.2024 | 31.03.2023 |
| | | Audited | Unaudited | Audited Refer note no 7 | Audited | Audited Refer to note no 7 |
| A) Part-1 Consolidated Statement of Audited Financial Results for the Quarter and Year Ended March 31, 2024 | | | | | | |
| 1 | Income from Operations | | | | | |
| | (a) Net Sales and Services from Operations | 10,193.78 | 9,704.59 | - | 36,735.36 | - |
| | (b) Other Operating Income | 29.75 | 29.00 | - | 124.12 | - |
| | Total Income from Operations (net) (a+b) | 10,223.53 | 9,733.59 | - | 36,859.48 | - |
| 2 | Expenses | | | | | |
| | (a) Cost of Materials Consumed | 5,155.00 | 4,664.80 | - | 22,475.54 | - |
| | (b) Purchase of Stock in trade | 802.02 | 198.90 | - | 1,065.35 | - |
| | (c) Changes in Inventories of, Finished Goods, and Work In Progress and Stock-in-trade | (91.28) | 2,062.81 | - | 910.33 | - |
| | (d) Employee Benefits Expenses | 1,110.65 | 897.12 | - | 3,907.13 | - |
| | (e) Depreciation and amortization expenses | 386.43 | 362.85 | - | 1,465.08 | - |
| | (f) Other Expenses | 2,077.53 | 1,212.17 | - | 6,761.47 | - |
| | Total Expenses (a to f) | 9,440.35 | 9,398.65 | - | 36,584.90 | - |
| 3 | Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2) | 783.18 | 334.94 | - | 274.58 | - |
| 4 | Other Income | 4.76 | 0.19 | - | 9.80 | - |
| 5 | Profit / (Loss) from ordinary activities before finance costs and exceptional items (3+4) | 787.94 | 335.13 | - | 284.38 | - |
| 6 | Finance costs (net) | 395.08 | 330.95 | - | 1,391.70 | - |
| 7 | Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5-6) | 392.86 | 4.18 | - | (1,107.32) | - |
| 8 | Exceptional items | - | - | - | - | - |
| 9 | Profit/(Loss) from ordinary activities before tax (7-8) | 392.86 | 4.18 | - | (1,107.32) | - |
| 10 | Tax Expenses | | | | | |
| | Current Tax | 19.85 | (10.61) | - | 19.85 | - |
| | Deferred Tax | 20.00 | (35.00) | - | (220.00) | - |
| | Total Tax Expenses (a+b) | 39.85 | (45.61) | - | (200.15) | - |
| 11 | Net Profit(+)/Loss(-) from ordinary activities after tax (9-10) | 353.01 | 49.79 | - | (907.17) | - |
| 12 | Extraordinary Items | - | - | - | - | - |
| 13 | Net Profit(+)/Loss (-) for the period(11-12) | 353.01 | 49.79 | - | (907.17) | - |
| 14 | Share of Profit / (Loss) of associates | - | - | - | - | - |
| 15 | Minority Interest | - | - | - | - | - |
| 16 | Net Profit / (Loss) after taxes, minority interest and share of profit / -(loss) of associates (13-14- | 353.01 | 49.79 | - | (907.17) | - |
| 17 | Other Comprehensive income not reclassified into Profit and loss account (Net of Taxes) | (65.33) | 3.12 | - | (55.97) | - |
| | Total Comprehensive Income (16+17) | 287.68 | 52.91 | - | (963.14) | - |
| 18 | Paid-up Equity Share Capital (Face value of Rs 10/- per share) | 1,582.82 | 1,582.82 | - | 1,582.82 | - |
| 19 | Reserve excluding Revaluation Reverses as per balance sheet of previous accounting year | - | - | - | 11,996.46 | - |
| 20 | Earnings Per Share (EPS) (of Rs 10/-each not annualised): | | | | | |
| | (a) Basic | 2.23 | 0.31 | - | (5.73) | - |
| | (b) Diluted | 2.23 | 0.31 | - | (5.73) | - |





Consolidated Cash Flow Statement For the Period Ended March 31, 2024

(Rs. In Lakhs)

| Particulars | For the Period September 30, 2023 to March, 31, 2024 Audited | For the Period ended March 31, 2023 Audited |
|--|---|---|
| A. Cash flow from operating activities | | |
| Net profit before tax and extra ordinary items. | 397.05 | - |
| Add / (Less) : | | |
| Depreciation & amortisation | 749.28 | - |
| Interest expenses (net) | 726.03 | - |
| Dividend Income | (0.04) | - |
| (Gain)/loss on sale of fixed assets | 7.03 | - |
| Asset Discarded | - | - |
| (Gain)/loss on sale of investments | - | - |
| Prov of Diminution in value of Investment | - | - |
| Remeasurements of the defined benefit plans | (87.77) | - |
| Operating profit before working capital changes | 1,791.57 | - |
| Adjustment for : | | |
| (Increase)/decrease in short term loans and advances | (106.69) | - |
| (Increase)/decrease in other current assets | 1,242.61 | - |
| (Increase)/decrease in trade receivables | 104.67 | - |
| (Increase)/decrease in inventory | 1,688.76 | - |
| (Increase)/decrease in other non-current assets | 56.83 | - |
| Increase/(decrease) in Other Equity | - | - |
| Increase/(decrease) in trade payables | (2,018.00) | - |
| Increase/(decrease) in other current liabilities | (2,325.67) | - |
| Increase/(decrease) in provisions | 124.80 | - |
| Increase/(decrease) in current lease liabilities | (137.28) | - |
| Increase/(decrease) in non-current liabilities | 97.80 | - |
| Increase/(decrease) in deposits | - | - |
| Increase/(decrease) in non current lease liabilities | (146.49) | - |
| | (1,418.66) | - |
| Cash generated from operations | 372.91 | - |
| Add / (Less) : | | |
| Income Tax (Paid)/ Refund | (9.24) | - |
| Net cash from operating activities | 363.68 | - |
| B. Cash flow from investing activities : | | |
| Purchase of fixed assets including Capital WIP | (1,183.27) | - |
| Sale of fixed assets | 0.50 | - |
| Sale/(Purchase) of investments | (0.01) | - |
| Dividend Income | 0.04 | - |
| Net cash from investing activities | (1,182.74) | - |
| C. Cash flow from financing activities : | | |
| Proceeds/(repayment) of short term borrowing | 1,694.01 | - |
| Proceeds/(repayment) of long term borrowing | (445.32) | - |
| Interest Paid (net) | (726.03) | - |
| Dividend paid | - | - |
| Issue of Share | - | - |
| Net cash used in financing activities | 522.67 | - |
| Net increase / (decrease) in cash and cash equivalents | (296.39) | - |
| Cash and cash equivalents - opening balance | 386.78 | - |
| Cash and cash equivalents - closing balance | 90.38 | - |
| Details of cash and cash equivalent at the end of the Period / Year | | |
| - Cash in hand | 6.71 | - |
| - Balance in current and fix deposit accounts | 83.68 | - |
| Total | 90.38 | - |




MANGALAM DRUGS AND ORGANICS LIMITED

CIN - L24230MH1972PLC116413

Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400001.

**Notes :**

| | |
|---|---|
| 1 | The above financial results have been prepared in accordance with Indian Accounting Standard (Ind AS) notified under section 133 of the companies Act, 2013, read together with Companies (Indian Accounting Standard) Rules, 2015 and relevant amendment rules thereafter. |
| 2 | The above audited Consolidated financial results of the Company for the Quarter and year ended have been reviewed by the Audit Committee and thereafter, approved and taken on record by the Board of Directors of the Company (Mangalam Drugs and Organics Limited) at their meeting held on May 21, 2024. |
| 3 | The Company's business activity falls within a single reportable Business Segment Viz. "Manufacturing of Bulk Drugs". |
| 4 | The figures for the quarter ended 31st March, 2024 are the balancing figures between the Audited figures in respect of full financial year upto 31st March 2024 and the unaudited published year-to-date figures upto 31st December 2023 being the date of the end of the third quarter of the financial year respectively whichever subjected to limited review. |
| 5 | Consolidated results includes results of Mangalam Laboratories Private Limited ,subsidiary for the purpose of Consolidated results. |
| 6 | As on september 30,2023 the Company has acquired 3010 Equity shares of Mangalam Laboratories Private Limited of Rs. 100 each. Mangalam Laboratories Private Limited became a wholly owned subsidiary of the Company .The wholly owned subsidiary is not a material subsidiary of the company on acquisition. |
| 7 | Since the Company, has acquired control on September 30, 2023 hence consolidation is applicable only from September 30,2023.Figures for the quarter ended March 31, 2023, year ended 31.03.23 in respect of Statement of profit & loss account and Statement of assets and liabilities are not applicable to the Company.Consolidated cash flow statement is applicable only from September 30 ,2023 till 31stt March 2024 |
| 8 | The Board of Directors of the Company at its meeting held on March 15, 2024 had considered and approved the scheme of Merger by Absorption of Mangalam Laboratories Private Limited ("First Transferor Company") and Shri JB Pharma Private Limited (Formerly known as Shri JB Pharma LLP) ("Second Transferor Company") with Mangalam Drugs and Organics Limited ("Transferee Company") and their respective shareholders under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013. The Scheme is subject to the necessary statutory and regulatory approvals including the approvals of Hon'ble National Company Law Tribunal, the shareholders and creditors of each of the companies. As on date, the Scheme is pending for disposal at both Stock Exchanges who shall issue No Objection Certificate under Regulation 37 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 |

Place:Mumbai
Date: May 21 ,2024On behalf of Board of Directors
For Mangalam Drugs and Organics Limited
Shri Govardhan M. Dhoot
Chairman and Managing Director
DIN:01240086



Independent Auditor's Report on Quarterly and Year to Date Consolidated Audited Financial Results of Mangalam Drugs and Organics Limited for the year ended 31st March, 2024 pursuant to the Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015

To the Boards of Directors,

Mangalam Drugs and Organics Limited
Rupam Building, 3rd Floor,
239, P. D'Mello Road, Mumbai 400 001.

Report on the audit of the Consolidated Financial Results

Opinion

We have audited the accompanying consolidated annual financial results of **Mangalam Drugs and Organics Limited** (hereinafter referred to as "the Holding Company"), its subsidiary (the Holding Company and its subsidiary together referred to as "the Group") and its share of the net loss after tax and total comprehensive income of its subsidiary for the year ended from 1st April, 2023 to 31st March, 2024 ("the Statement") being submitted by the Parent pursuant to the requirements of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"), as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10th August 2021.

In our opinion, and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors on separate audited financial statements of the subsidiary the aforesaid consolidated annual financial results:

- include the annual financial results of the Mangalam Laboratories Private Limited, a Subsidiary Company to the aforesaid consolidated annual financial results;
- are presented in accordance with the requirements of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021 in this regard; and
- give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of consolidated net loss and other comprehensive income and other financial information of the Group for the year ended 31st March 2024.



Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (hereinafter referred to as "Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Consolidated Financial Statements" section of our report. We are independent of the Group and its subsidiary in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained, along with the consideration of reports of the other auditor referred to in sub paragraph no. (a) of the "Other Matters" paragraph below is sufficient and appropriate to provide a basis for our opinion.

Board of Director's Responsibility for the Consolidated Financial Statements

These consolidated annual financial results have been prepared on the basis of the consolidated annual financial statements. The Holding Company's Management and the Board of Directors are responsible for the preparation and presentation of these consolidated annual financial results that give a true and fair view of the consolidated net loss and other comprehensive income and other financial information of the Group including its subsidiary in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10th August 2021.

The respective Management and Board of Directors of the companies included in the Group of its subsidiary are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of each Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated annual financial results by the Management and the Board of Directors of the Holding Company, as aforesaid.

In preparing the consolidated annual financial results, the respective Management and the Board of Directors of the Companies included in the Group of its subsidiary are responsible for assessing the ability of each Company to continue as a going concern, disclosing, as applicable, matters related to Going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and the respective Management and Board of Directors of its subsidiary is responsible for overseeing the financial reporting process of each Company.



Auditor's Responsibility for the Audit of Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- A. Identify and assess the risks of material misstatement of the consolidated annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- B. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the Company had adequate internal financial control with reference to the financial Statements in place and the operating effectiveness of such controls.
- C. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the consolidated annual financial results made by the Management and Board of Directors.
- D. Conclude on the appropriateness of the Management and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its subsidiary to cease to continue as a going concern.
- E. Evaluate the overall presentation, structure and content of the consolidated annual financial results, including the disclosures, and whether the consolidated annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- F. Obtain sufficient appropriate audit evidence regarding the financial results of the entities within the Group and its subsidiary to express an opinion on the consolidated annual financial results. We are responsible for the direction, supervision and performance of the audit of financial results of such entities included in the consolidated annual financial results of which we are the independent auditors. For the other entities included in the consolidated annual financial results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out



by them. We remain solely responsible for our audit opinion. Our responsibilities in this regard are further described in sub paragraph (a) of the "Other Matters" paragraph in this audit report.

We communicate with those charged with governance of the Holding Company of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular No CIR/CFD/CMD1/44/2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.


Other Matters

- a. The consolidated Audited Financial Results includes the audited financial results of its subsidiary, whose financial statements reflects Total Assets (before consolidation adjustments) of Rs. 1744.04 Lakhs as at 31st March 2024, Total Revenue (before consolidation adjustments) of Rs. 4.20 Lakhs, Total Net Loss after tax (before consolidation adjustments) of Rs. 2.27 Lakhs, Total comprehensive loss (before consolidation adjustments) of Rs 2.27 Lakhs and Net Cash Inflows (before consolidation adjustments) of Rs. 2.72 Lakhs for the year ended on that date, as considered in the consolidated annual financial results, which have been audited by their respective independent auditor. The consolidated annual financial results also include the Group's share of Total Net Loss After Tax of Rs. 907.17 Lakhs for the year ended 31st March 2024 and Total Comprehensive Income of Rs 963.14 Lakhs as considered in the consolidated annual financial results, in respect of its subsidiary whose financial statements have been audited by their respective independent auditors. The independent auditor's reports on financial statements of these entity have been furnished to us by the management.

Our opinion on the consolidated annual financial results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the reports of such auditors and the procedures performed by us are as stated in paragraph above.

- b. The consolidated annual financial results include the results for the quarter ended 31st March 2024 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For V. S. SOMANI & CO.,
Chartered Accountants
Firm Registration No.: 117589



CA. VIDYADHAR SOMANI
Proprietor

Membership No: 102664
UDIN No. 24102664BKEIZU3645



Place: Mumbai
Date: May 21, 2024

Mangalam Drugs and Organics Limited



Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.

☎ 91-22-62616200 / 6300 / 8787 ☎ 91-22-62619090 • CIN : L24230MH1972PLC116413

Annexure II

Brief Profile of Internal Auditor of the Company for the Financial Year 2024-25

We further submit the following details as required under Regulation 30 of the SEBI (LODR), Regulation, 2015 read with Circular No, CIR / CFD / CMD / 4 / 2015 dated 9th September, 2015.

| | |
|-------------------------------------|--|
| Name of the Firm | Bipin Zavar & Associates, Chartered Accountants |
| Date of Appointment | 21.05.2024 |
| Financial Year | 2024-25 |
| Term of Appointment | As per Appointment Letter. |
| Reason of Change/Appointment | In accordance with the provisions of Section 138 of Companies Act, 2013, the Company has appointed Internal Auditor for conducting the Internal Audit of the Company for Financial Year 2024-25. |
| Brief Profile | M/s Bipin Zavar & Associates is a firm of experienced Chartered Accountants providing specialized services in the area of Audit & Assurance, direct and Indirect Tax, Business Advisory, Accounting and Regulatory compliances providing Specialized Quality Services with client needs and servicing at the center. |

Mangalam Drugs and Organics Limited



Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.

☎ 91-22-62616200 / 6300 / 8787 ☎ 91-22-62619090 • CIN : L24230MH1972PLC116413

Annexure III

Brief Profile of Secretarial Auditor of the Company for the Financial Year 2023-24

| | |
|--|---|
| Name of the Practicing Company Secretary | Ms. Rakhi Dasgupta |
| Address of the Firm | 218, Paschim Daspara, Nischintapur Road, Sonarpur, Kolkata- 700150 |
| E-Mail Id | csrakhidasgupta@gmail.com |
| Contact No | +91 62910-50996 |
| Founder Name | Rakhi Dasgupta |
| Membership No | A28739 |
| Certificate of Practice No. | 20354 |
| Work Profile | CS Rakhi Dasgupta provides various professional services the field of Corporate legal Compliance, Secretarial Audit, Corporate Governance Audit, Corporate Litigation, Corporate Restructuring, Obtaining Regulatory Approvals, Incorporation of Limited Companies and LLP etc. |
| Disclosure of Relationship with Directors | None |

Annexure IV

Large Corporate Disclosure

| Sr. No. | Particulars | Amount in Rs. |
|----------------|---|----------------------|
| 1. | Outstanding Qualified Borrowings at the start of the financial year | 18,76,63,031 |
| 2. | Outstanding Qualified Borrowings at the end of the Financial year | 13,35,45,995 |
| 3. | Highest credit rating of the company (where the credit rating relates to the unsupported bank borrowing or plain vanilla bonds of an entity, which have no structuring/ support built in) | BB+ |
| 4. | Incremental borrowing done during the year (qualified borrowing) | NA |
| 5. | Borrowings by way of issuance of debt securities during the year | NA |

The Company hereby declares that, it does not fall's under the purview of Large Corporate

Yours faithfully,
For **Mangalam Drugs & Organics Limited**

GOVARDHAN
MURLIDHAR
DHOOOT

Digitally signed by: GOVARDHAN
MURLIDHAR DHOOOT
DN: CN = GOVARDHAN
MURLIDHAR DHOOOT C = IN O =
Personal
Date: 2024.05.21 19:33:20 +05'30'

Govardhan M. Dhoot
Chairman & Managing Director
DIN: 01240086